Cargando…

Prospective observational study in patients with obstructive lung disease: NOVELTY design

Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global, prospective ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddel, Helen K., Gerhardsson de Verdier, Maria, Agustí, Alvar, Anderson, Gary, Beasley, Richard, Bel, Elisabeth H., Janson, Christer, Make, Barry, Martin, Richard J., Pavord, Ian, Price, David, Keen, Christina, Gardev, Asparuh, Rennard, Stephen, Sveréus, Alecka, Bansal, Aruna T., Brannman, Lance, Karlsson, Niklas, Nuevo, Javier, Nyberg, Fredrik, Young, Simon S., Vestbo, Jørgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355976/
https://www.ncbi.nlm.nih.gov/pubmed/30723727
http://dx.doi.org/10.1183/23120541.00036-2018
_version_ 1783391433652174848
author Reddel, Helen K.
Gerhardsson de Verdier, Maria
Agustí, Alvar
Anderson, Gary
Beasley, Richard
Bel, Elisabeth H.
Janson, Christer
Make, Barry
Martin, Richard J.
Pavord, Ian
Price, David
Keen, Christina
Gardev, Asparuh
Rennard, Stephen
Sveréus, Alecka
Bansal, Aruna T.
Brannman, Lance
Karlsson, Niklas
Nuevo, Javier
Nyberg, Fredrik
Young, Simon S.
Vestbo, Jørgen
author_facet Reddel, Helen K.
Gerhardsson de Verdier, Maria
Agustí, Alvar
Anderson, Gary
Beasley, Richard
Bel, Elisabeth H.
Janson, Christer
Make, Barry
Martin, Richard J.
Pavord, Ian
Price, David
Keen, Christina
Gardev, Asparuh
Rennard, Stephen
Sveréus, Alecka
Bansal, Aruna T.
Brannman, Lance
Karlsson, Niklas
Nuevo, Javier
Nyberg, Fredrik
Young, Simon S.
Vestbo, Jørgen
author_sort Reddel, Helen K.
collection PubMed
description Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329). NOVELTY's primary objectives are to describe patient characteristics, treatment patterns and disease burden over time, and to identify phenotypes and molecular endotypes associated with differential outcomes over time in patients with a diagnosis/suspected diagnosis of asthma and/or COPD. NOVELTY aims to recruit real-world patients, unlike clinical studies with restrictive inclusion/exclusion criteria. Data collected at yearly intervals include clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs) and healthcare utilisation (HCU). PROs and HCU will also be collected 3-monthly via internet/telephone. Data will be used to identify phenotypes and endotypes associated with different trajectories for symptom burden, clinical progression or remission and HCU. Results may allow patient classification across obstructive lung disease by clinical outcomes and biomarker profile, rather than by conventional diagnostic labels and severity categories. NOVELTY will provide a rich data source on obstructive lung disease, to help improve patient outcomes and aid novel drug development.
format Online
Article
Text
id pubmed-6355976
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-63559762019-02-05 Prospective observational study in patients with obstructive lung disease: NOVELTY design Reddel, Helen K. Gerhardsson de Verdier, Maria Agustí, Alvar Anderson, Gary Beasley, Richard Bel, Elisabeth H. Janson, Christer Make, Barry Martin, Richard J. Pavord, Ian Price, David Keen, Christina Gardev, Asparuh Rennard, Stephen Sveréus, Alecka Bansal, Aruna T. Brannman, Lance Karlsson, Niklas Nuevo, Javier Nyberg, Fredrik Young, Simon S. Vestbo, Jørgen ERJ Open Res Study Protocol Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329). NOVELTY's primary objectives are to describe patient characteristics, treatment patterns and disease burden over time, and to identify phenotypes and molecular endotypes associated with differential outcomes over time in patients with a diagnosis/suspected diagnosis of asthma and/or COPD. NOVELTY aims to recruit real-world patients, unlike clinical studies with restrictive inclusion/exclusion criteria. Data collected at yearly intervals include clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs) and healthcare utilisation (HCU). PROs and HCU will also be collected 3-monthly via internet/telephone. Data will be used to identify phenotypes and endotypes associated with different trajectories for symptom burden, clinical progression or remission and HCU. Results may allow patient classification across obstructive lung disease by clinical outcomes and biomarker profile, rather than by conventional diagnostic labels and severity categories. NOVELTY will provide a rich data source on obstructive lung disease, to help improve patient outcomes and aid novel drug development. European Respiratory Society 2019-02-01 /pmc/articles/PMC6355976/ /pubmed/30723727 http://dx.doi.org/10.1183/23120541.00036-2018 Text en Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Study Protocol
Reddel, Helen K.
Gerhardsson de Verdier, Maria
Agustí, Alvar
Anderson, Gary
Beasley, Richard
Bel, Elisabeth H.
Janson, Christer
Make, Barry
Martin, Richard J.
Pavord, Ian
Price, David
Keen, Christina
Gardev, Asparuh
Rennard, Stephen
Sveréus, Alecka
Bansal, Aruna T.
Brannman, Lance
Karlsson, Niklas
Nuevo, Javier
Nyberg, Fredrik
Young, Simon S.
Vestbo, Jørgen
Prospective observational study in patients with obstructive lung disease: NOVELTY design
title Prospective observational study in patients with obstructive lung disease: NOVELTY design
title_full Prospective observational study in patients with obstructive lung disease: NOVELTY design
title_fullStr Prospective observational study in patients with obstructive lung disease: NOVELTY design
title_full_unstemmed Prospective observational study in patients with obstructive lung disease: NOVELTY design
title_short Prospective observational study in patients with obstructive lung disease: NOVELTY design
title_sort prospective observational study in patients with obstructive lung disease: novelty design
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355976/
https://www.ncbi.nlm.nih.gov/pubmed/30723727
http://dx.doi.org/10.1183/23120541.00036-2018
work_keys_str_mv AT reddelhelenk prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT gerhardssondeverdiermaria prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT agustialvar prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT andersongary prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT beasleyrichard prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT belelisabethh prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT jansonchrister prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT makebarry prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT martinrichardj prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT pavordian prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT pricedavid prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT keenchristina prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT gardevasparuh prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT rennardstephen prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT svereusalecka prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT bansalarunat prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT brannmanlance prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT karlssonniklas prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT nuevojavier prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT nybergfredrik prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT youngsimons prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign
AT vestbojørgen prospectiveobservationalstudyinpatientswithobstructivelungdiseasenoveltydesign